[صفحه اصلی ]   [Archive]  
:: صفحه اصلي :: درباره نشريه :: آخرين شماره :: تمام شماره‌ها :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
بخش‌های اصلی
صفحه اصلی::
اطلاعات نشریه::
برای نویسندگان::
آرشیو مجله و مقالات::
برای داوران::
ثبت نام و اشتراک::
تماس با ما::
تسهیلات پایگاه::
بایگانی مقالات زیر چاپ::
::
جستجو در پایگاه

جستجوی پیشرفته
..
دریافت اطلاعات پایگاه
نشانی پست الکترونیک خود را برای دریافت اطلاعات و اخبار پایگاه، در کادر زیر وارد کنید.
..
:: دوره 14، شماره 1 - ( 10-1401 ) ::
جلد 14 شماره 1 صفحات 82-76 برگشت به فهرست نسخه ها
Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial
چکیده:   (1645 مشاهده)
Background: Previous researche showed some clinical benefits regarding the nephroprotective effect of melatonin. So, this study aimed to evaluate the beneficial effect of oral melatonin on preventing acute kidney injury (AKI) in patients who received vancomycin therapy in the intensive care unit (ICU).
Methods: We performed a randomized, double-blinded, placebo-controlled pilot study in an academic hospital. Adult patients admitted to the ICU who received vancomycin with normal gastrointestinal and kidney function were randomized into treatment or placebo groups. After that, enrolled patients received a tablet of melatonin (3 mg) or placebo twice daily for seven consecutive days.
 The occurrence of AKI was assessed by RIFLE criteria (by measurement of serum creatinine (SCr)) and plasma neutrophil gelatinase-associated lipocalin (NGAL) concentration. Moreover, other data related to renal functions and SOFA were also compared between groups.
Results: A total of 90 patients were included in the study, while 21patients in the placebo group and 20 in the intervention group completed the study. There were no significant differences between groups regarding baseline SCr, BUN, urine output, NGAL, SOFA, and glomerular filtration rate (GFR). Our results showed that these differences remained insignificant after a 7-day follow-up between groups. However, the incidence of AKI was significantly lower in the melatonin group based on the NGAL cutoff (> 150 ng/mL).
Conclusion: We detected a significant decrease in vancomycin-induced nephrotoxicity incidence in patients receiving melatonin compared to placebo. However, more clinical trials in a larger population were required to confirm this result.
متن کامل [PDF 263 kb]   (619 دریافت)    
نوع مطالعه: Original Article | موضوع مقاله: Nephrology
دریافت: 1400/10/6 | پذیرش: 1400/11/30 | انتشار: 1401/11/1
ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

CAPTCHA



XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbasi S, Bigharaz E, Farsaei S, mansourian M. Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial. Caspian J Intern Med 2023; 14 (1) :76-82
URL: http://caspjim.com/article-1-3291-fa.html

Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial. 1. 1401; 14 (1) :76-82

URL: http://caspjim.com/article-1-3291-fa.html



بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.
دوره 14، شماره 1 - ( 10-1401 ) برگشت به فهرست نسخه ها
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 37 queries by YEKTAWEB 4645